Immatics (IMTX) Expected to Announce Quarterly Earnings on Monday

Immatics (NASDAQ:IMTX) is anticipated to release its Q3 2025 results before the market opens on Monday, November 17th. Analysts expect Immatics to post earnings of ($0.50) per share and revenue of $12.5270 million for the quarter. Parties can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Friday, November 21, 2025 at 9:30 AM ET.

Immatics (NASDAQ:IMTX) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.28). The company had revenue of $6.48 million for the quarter, compared to analyst estimates of $13.05 million. Immatics had a negative net margin of 59.29% and a negative return on equity of 15.60%. On average, analysts expect Immatics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Immatics Price Performance

Immatics stock opened at $10.20 on Friday. Immatics has a fifty-two week low of $3.30 and a fifty-two week high of $11.25. The firm’s 50 day simple moving average is $8.81 and its 200-day simple moving average is $6.77. The company has a market cap of $1.24 billion, a P/E ratio of -15.69 and a beta of 1.24.

Institutional Trading of Immatics

Large investors have recently added to or reduced their stakes in the company. Sofinnova Investments Inc. boosted its stake in Immatics by 44.1% in the 2nd quarter. Sofinnova Investments Inc. now owns 2,240,528 shares of the company’s stock valued at $12,054,000 after purchasing an additional 686,224 shares during the period. Wasatch Advisors LP grew its stake in shares of Immatics by 35.9% in the second quarter. Wasatch Advisors LP now owns 785,154 shares of the company’s stock valued at $4,224,000 after acquiring an additional 207,491 shares in the last quarter. JPMorgan Chase & Co. increased its position in Immatics by 31.5% during the second quarter. JPMorgan Chase & Co. now owns 198,769 shares of the company’s stock worth $1,069,000 after acquiring an additional 47,590 shares during the period. BNP Paribas Financial Markets raised its position in Immatics by 56.8% during the third quarter. BNP Paribas Financial Markets now owns 122,510 shares of the company’s stock valued at $1,044,000 after purchasing an additional 44,387 shares in the last quarter. Finally, Engineers Gate Manager LP bought a new stake in Immatics during the second quarter worth $124,000. Institutional investors and hedge funds own 64.41% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on IMTX shares. Zacks Research upgraded shares of Immatics from a “strong sell” rating to a “hold” rating in a report on Monday, October 13th. Mizuho set a $19.00 target price on Immatics in a research note on Wednesday, October 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immatics in a research report on Wednesday, October 8th. Finally, Guggenheim initiated coverage on Immatics in a report on Thursday, September 18th. They set a “buy” rating and a $16.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Immatics has a consensus rating of “Moderate Buy” and an average target price of $15.00.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.